Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors by Codoner, Francisco M. et al.
1Scientific RepoRts | 7: 3717  | DOI:10.1038/s41598-017-03260-4
www.nature.com/scientificreports
Gag-protease coevolution analyses 
define novel structural surfaces 
in the HIV-1 matrix and capsid 
involved in resistance to Protease 
Inhibitors
Francisco M Codoñer1,2, Ruth Peña3, Oscar Blanch-Lombarte3, Esther Jimenez-Moyano3, 
Maria Pino3, Thomas Vollbrecht4,5, Bonaventura Clotet3,6, Javier Martinez-Picado3,6,7, Rika 
Draenert8 & Julia G. Prado3
Despite the major role of Gag in establishing resistance of HIV-1 to protease inhibitors (PIs), very limited 
data are available on the total contribution of Gag residues to resistance to PIs. To identify in detail Gag 
residues and structural interfaces associated with the development of HIV-1 resistance to PIs, we traced 
viral evolution under the pressure of PIs using Gag-protease single genome sequencing and coevolution 
analysis of protein sequences in 4 patients treated with PIs over a 9-year period. We identified a total 
of 38 Gag residues correlated with the protease, 32 of which were outside Gag cleavage sites. These 
residues were distributed in 23 Gag-protease groups of coevolution, with the viral matrix and the capsid 
represented in 87% and 52% of the groups. In addition, we uncovered the distribution of Gag correlated 
residues in specific protein surfaces of the inner face of the viral matrix and at the Cyclophilin A binding 
loop of the capsid. In summary, our findings suggest a tight interdependency between Gag structural 
proteins and the protease during the development of resistance of HIV-1 to PIs.
The introduction of protease inhibitors (PIs) as part of the highly active antiretroviral therapy (HAART) have led 
to a dramatic reduction in morbidity and mortality rates in HIV-1–infected patients1. PIs have high intrinsic anti-
viral activity and are among the most potent antiretroviral drugs (ART) available in clinical practice to date. In 
fact, only simplification strategies with boosted PIs have proven to be as efficacious as triple ART in maintaining 
continuous virological suppression2, 3.
PIs target the active site of the HIV-1 protease (PR). Protease activity is essential for the generation of full 
infectious viral particles through the cleavage of Gag and Gag-pol polyproteins. Despite the high genetic barrier 
of the PI, the emergence of mutations at the protease active site leads to drug resistance. Mutations in HIV-1 caus-
ing resistance to PIs reduce the affinity of the drug for the active site. These mutations are generally followed by a 
stepwise accumulation of additional mutations in protease that partially rescue its activity4. Moreover, mutations 
in the Gag polyprotein at protease cleavage sites have generally been shown to contribute to resistance to PIs by 
restoring the interaction with the cleavage sites and compensating for defects in viral replicative capacity5, 6.
However, the above-mentioned “traditional” PI resistance pathways have been challenged by studies that evi-
dence virological failure of PI-treated patients in the absence of PI resistance mutations7. Various studies have 
demonstrated the direct contribution of Gag mutations to drug susceptibility. Thus, mutations at Gag cleavage site 
positions A431V, K436E and I437V/T conferred resistance to PIs in the absence of drug resistance mutations at 
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the active site of the protease7–9. Moreover, central residues of the Gag matrix (R76K, Y79F, and T81A) have been 
directly associated with reduced susceptibility to PIs and increased viral replicative capacity10, 11. These “alterna-
tive” PI resistance pathways have been shown to include mutations in the cytoplasmic tail of gp41 that can alter 
interactions between gp41 and Gag, thus affecting viral entry12, 13. The previous studies evidence the importance 
of HIV-1 Gag in the mechanisms of susceptibility to PIs and support the association of Gag and protease as a 
functional unit. Furthermore, these studies demonstrate that, despite many years since the introduction of PIs, 
the determinants of virological failure have not been fully characterized.
To gain new insights into the identification of novel determinants in Gag associated with resistance to PIs, we 
traced virus evolution by combining Gag-protease bulk and single genome sequencing with coevolution analysis 
of protein sequences in 4 patients treated with PIs over a 9-year period. Using this approach, we determined hot-
spots of protease coevolution under pressure from PIs in Gag structural proteins, mainly in the matrix, but also 
in the capsid. Moreover, 3-dimensional information on coevolving sites in the matrix and the capsid shed light on 
the structural and functional constraints governing Gag coevolution under pressure from PIs.
Results
HIV-1 mutations at Gag cleavage and non-cleavage sites emerge concomitantly in vivo during 
resistance to PIs. We first investigated mutational changes in HIV-1 during the development of resistance to 
PIs and their distribution across Gag and protease regions. We sequenced the HIV-1 Gag-protease coding region 
from longitudinal plasma samples in 4 patients (PT1 to PT4) over a 9-year period of antiretroviral treatment 
containing PIs (Fig. 1A). Sequence analysis confirmed the stepwise accumulation of Gag cleavage site mutations 
(CSM) at the following positions: V128I at p17/p24; S373P, I376V at p2/NC; and A431V NC/p1, K436R NC/
p1 and P453A at p1/p6. Of these Gag CSM, A431V was previously associated with drug resistance mutations at 
positions M46I/L and V82A/T in the protease, K436R was associated with the mutation V82A, and P453A was 
associated with the drug resistance mutations I84V and L90M in the protease4. Indeed, CSM associated with drug 
resistance mutations in the protease have been previously associated with PI exposure in vivo and in some cases 
(V128I, A431V, K436R, P453A) with PI resistance4. Mutational evolution of the virus in all patients rendered 
virus multiresistant to all PIs over time, with the exception of darunavir (Stanford HIVdb Genotypic Resistance 
Interpretation Algorithm, data not shown).
Figure 1. Gag cleavage sites and protease mutations in long-term PI-experienced HIV-1–infected patients. 
(A) Clinical follow-up of patients. Blue lines show HIV-1 viral load and orange lines show CD4+ T-cell counts. 
The grey bar on top represents time on antiretroviral treatment containing PIs. Arrows and numbers indicate 
the time points of the samples tested in the study. (B) HIV-1 Gag cleavage site mutations and PI resistance 
mutations. The top line shows the sequence numbering according to the HXB2 reference sequence for all 
HIV-1 Gag cleavage sites. Cleavage site mutations (CSM) are indicated by letters. Bold letters identify the CSM 
previously associated with exposure to PIs. Only PI resistance mutations in the protease are shown on the right 
column. AZT, zidovudine; 3TC, lamivudine, ddC, zalcitabine; ddI, didanosine; d4T, stavudine; EFV, efavirenz; 
TDF, tenofovir; ABC, abacavir; SQV, saquinavir; RTV, ritonavir; IDV, indinavir; LPV/r, lopinavir; NFV, 
nelfinavir; APV, amprenavir.
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However, the patterns and distribution of mutations in Gag varied between the patients. In PT1, we observed 
the emergence of HIV-1 Gag CSM at positions V128I (p17/p24) and A431V (NC/p1), together with the selection 
of the resistance mutations I54V and V82A in the protease during treatment with RTV (Fig. 1B). Moreover, the 
selection of S373P (p2/NC) in this patient matched the introduction of LPV/r. In the case of PT2, Gag CSM S373P 
(p2/NC) was present before the selection of A431V (NC/p1) and V82F in the protease after the introduction of 
IDV4. The presence of S373P before introduction of IDV could be associated with the polymorphic nature of this 
residue in treatment-naïve individuals14. Therefore, S373P could be selected in the absence of PIs, thus conferring 
a transitory advantage for the selection of protease drug resistance mutations, as suggested by the association of 
S373P to weaker virological responses to SQV/r15. The stepwise accumulation of I376V (p2/NC), V128I (p17/
p24) and P453A (p1/p6) in PT2 supports the emergence of complex mutational patterns in the protease, includ-
ing I54A, V82F, I84V and L90M. In contrast, for PT3, I437V was present, and the selection of K436R (NC/p1) in 
Gag CSM was concomitant with the emergence of the I84V mutation during treatment with LPV/r. No mutations 
were observed at the Gag cleavage sites in PT4 (Fig. 1B).
Next, we aimed to identify the regions in Gag with preferential accumulation of mutations derived from exposure 
to PIs. We performed a comparative analysis of Gag sequence evolution by comparison of bulk sequences before and 
after the introduction of PIs in each patient. We observed how amino acid variation concentrated in p2 (28.57%), 
followed by NC (14.55%), p17 (14.39%) and p6 (13.46%). We found very limited variation in p24 (2.61%) (Table 1). 
After the exclusion of Gag cleavage site positions from the analysis, sequence variation concentrated in p17 (12.12%) 
followed by NC (10.91%) and p6 (11.54%). We observed no differences in p24 (2.61%). The limited variation 
observed in p24 may be associated with the extreme genetic fragility of the protein to mutational changes16. Overall, 
these data indicate that both Gag CSM and non-CSM are required for the development of resistance to PIs by HIV-1.
HIV-1 Gag coevolving residues identify the matrix protein as the major contributor to protease 
evolution under selective pressure from PIs. We performed Coevolution Analyses for Protein Sequences 
(CAPS) to accurately identify correlated Gag residues involved in the evolution of the protease and resistance to 
PIs. This method has previously been applied in numerous case studies similar to ours17–19, and further detail on the 
methodology of CAPS analysis can be found in the Methods section. Thus, we analysed 171 HIV-1 Gag-protease 
sequences obtained by single-genome amplification (SGA) using CAPS. The sequences were equally distributed 
across patients and across the times from initiation of therapy with PIs (PT1, n = 44; PT2, n = 38; PT3, n = 41; and 
PT4, n = 48). We used SGA to avoid PCR resampling and recombination events, as previously reported20, and to 
accurately assess inter-protein mutational linkage, which is difficult to address in independent short reads21, 22.
By using CAPS on our sequence dataset, we were able to capture previous correlations of Gag with the pro-
tease at cleavage site positions V128 (p17/p24), S373 and S374 (p2/NC), Q450, S451 and P453 (p1/p6) (Fig. 2)4, 
which we used as quality benchmark of our analytical tools. Moreover, our analyses established significant corre-
lations with a total of 38 residues across Gag domains. Of those residues, 19 (50%) were located in the p17 viral 
matrix, 6 (16%) were located in the p24 viral capsid and 13 (34%) were distributed across p2/NC/p1/p6 proteins 
(Fig. 2A). In addition, 32 out of 38 residues were located outside Gag cleavage sites, thus, indicating the impor-
tance of Gag residues outside cleavage sites in protease coevolution. Further details on the specific residues are 
shown in Fig. 2B, including the entropy of the site and site frequency among Gag-protease coevolving groups. 
Of note, positions with a frequency over 15% in coevolving groups include residues 55, 69, 91, 120, 121, 123, 
and 124 in p17; residues 215, 228, 248 and 280 in p24; and residues 370, 373, 374, 450, 453, and 465 in p2/NC/
p1/p6 (Fig. 2B). Thus, these data support the role of p17 as the major contributor to protease evolution in terms 
of the total number of Gag correlated residues and their frequency among coevolving groups. Moreover, the 
lack of association between residue frequency in coevolving groups and Shannon entropy at the site (r2 = 0.08, 
rho = −0.29, data not shown) rules out the potential linkage between site-preferential coevolution and site varia-
bility, thus suggesting a direct effect of pressure from PIs on Gag-protease coevolution.
HIV-1 Gag coevolving residues define specific protein surfaces in the matrix and capsid. Next, 
we defined Gag-protease groups of coevolution and investigated their distribution at the protein 3-dimensional 
level. The 38 pairs of correlated residues organized in a total of 23 Gag-protease coevolving groups. These groups 
are defined by pairs of correlated residues sharing significant correlations among all pairs within the group.
Gag Length
Amino 
acid 
changes
Amino 
acid 
changes 
outside 
CS
Total 
variation 
(%)
Variation 
outside CS 
(%)
p17 132 19 16 14.39 12.12
p24 230 6 6 2.61 2.61
p2 14 4 1 28.57 7.14
NC 55 8 6 14.55 10.91
p1 16 1 0 6.25 0
p6 52 7 6 13.46 11.54
Table 1. Amino acid variation in Gag proteins. Amino acid changes were calculated as the median of individual 
changes per patient by direct comparison with the naïve PI sequence per each patient. (%) Frequency of 
variation was calculated as the number of amino acid changes in relation to protein length. CS, Cleavage sites
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The detailed composition of Gag-protease coevolving groups is shown in Fig. 3A. Groups of coevolution G1 to 
G4 included residues in the protease that were already associated with resistance to PIs (I54, M46, V82, and G48). 
In addition, G6, G8 and G23 included polymorphic sites in the protease (G6, L33; G8, V11 and K43; and G23, 
N83). Of note, 78% of the coevolving groups included two or more Gag domains and a single protease residue 
(Fig. 3A). Moreover, G20 to G23 had one residue in p17 (120, 126, 111 and 91) and one in the protease (69, 10, 77 
and 83), further supporting coevolutionary constraints between p17 and the protease during treatment with PIs.
To further understand specific groups of coevolution, we performed an analysis of individual groups in pre-
viously solved crystal structures of p17, p24 and the protease. We selected G1 and G2, as they contain residues 
54 and 46, which are directly associated with resistance to PIs. As shown in Fig. 3B, for G1 sites of coevolution 
between I54 and Gag include positions 55, 69, 91, 120 and 123 in p17 and 215, 228, 248, 252, 280 and 331 in p24. 
Residues 55, 92 and 91 in p17 are located in the globular domain. Indeed, residue 55 in helix 3, which is at the 
centre of the globular domain, interacts with helix 4 and is important for the structural stability of the protein23. 
By contrast, residues 69, 91 and 120 and 123, which are located at the α3/4 loop, 4/5 loop and helix 5, respec-
tively, in p17, share properties of structural flexibility. Residues 215, 228, 248 and 252 in p24 are located at the 
Cyclophilin-A (CypA) binding loop or nearby. These residues are essential for binding with cellular CypA and 
the early events of HIV-1 replication24. Moreover, residues 280 and 331, which bridge the NTD and the CTD of 
p24, share properties of structural flexibility in the protein. Additionally, for G2 sites of coevolution between M46 
and Gag include residues 66, 69, 111 and 124 in p17 and 280 in p24 (Fig. 3B). In this group, all Gag residues were 
located at regions of structural flexibility, which include the α3/4 loop (66, 69), helix 5 (111, 124) in p17 and the 
linker domain between NTD and CTD (280).
To extrapolate these initial findings to a general model for HIV-1 Gag-protease coevolution, we pooled coev-
olving Gag residues and investigated their distribution at the protein structural level. Structural mapping of all 
the coevolving residues in p17 and p24 identified a specific distribution of correlated sites. Coevolving residues in 
p17 were distributed across helix 1 (12, 15), helix 3 (55, 58), the α3/4 loop (65, 69), the interconnection domain 
4/5 loop (91, 93) and helix 5 (98, 102, 104, 111, 115) (Fig. 4A). Furthermore, coevolving positions in p24 defined 
clusters of residues in the CypA binding loop (215, 228) and its neighbouring helix 6 (248) and the  intercon-
nection domain helix 6/7 (252). These findings support previous data demonstrating the contribution of Cyp-A 
binding loop mutations in compensating for fitness defects of PI-resistant viruses25. Moreover, only two coev-
olving residues in p24 were outside this region. Residues 280 and 331 at the interconnection domain of helix 7/8 
and capping box of the helix 10 (Fig. 4B), which link the NTD and the CTD domains of p24, provide structural 
flexibility to the protein.
Similarly, at the quaternary protein structural level, the mapping of coevolving Gag residues revealed an 
organized spatial distribution (Fig. 4C,D). Thus, correlated residues in the matrix identified specific protein 
sectors or protein surfaces on the inner face of the trimer (Fig. 4C). The distribution suggests the presence of 
inter-protein interfaces among viral proteins. In contrast, the distribution of coevolving residues in the capsid at 
the CypA binding loop and nearby (Fig. 4D) on exposed surface areas may indicate functional constraints to reg-
ulate CypA incorporation in the virions. Overall, these data suggest specific structural and functional constraints 
in the matrix and the capsid driven by the development of protease resistance to PIs.
Figure 2. HIV-1 Gag correlated residues with protease. (A) Distribution of correlated residues in the Gag 
polyprotein. Left Y-axis coloured lines show the frequency of correlated residues in Gag among coevolving 
groups (%). Right Y-axis with grey lines shows the Shannon entropy of the correlated residues. Coloured lines 
indicate correlated residues; p17 in blue, p24 in orange, and p2, NC, p1 and p6 in green. (B) Specific residues of 
Gag correlated sites with the protease. Coloured squares indicate the frequency of the sites. Grey dots indicate 
the entropy of the sites. The line indicates the 15% frequency. Asterisks indicate residues at Gag cleavage sites. 
Numbering is according to the HXB2 reference sequence.
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Gag-protease coevolution during treatment with PIs is independent of HIV-1-specific 
CD8+T-cell immune pressure. The immunodominant nature of Gag in the generation of HIV-1–specific 
CD8+ T-cell responses argues for a potential contribution of cellular immune pressure to the evolution of the 
virus during treatment with PIs and detectable viral load. We measured cellular immune responses in PBMC 
using ELISpot with a panel of overlapping peptides (OLP) covering the Gag and protease regions to evaluate 
HIV-1 Gag evolutionary convergence between HIV-1–specific CD8+ T-cell immune pressure and drug pressure 
during the 9 years of treatment with PIs.
Figure 3. Coevolving groups of Gag-protease residues and protein structural mapping. (A) Coevolving Gag-
protease groups. Protein residues within groups are indicated by coloured hexagons (blue for p17, orange 
for p24, and green for p1/NC/p2/p6). Grey squares indicate groups with protease residues associated with 
resistance of HIV-1 protease to PIs. Numbers in bold indicate positions previously associated with resistance 
and/or exposure to PIs. (B) Solved crystal structure of p17 (PDB 1HIW), p24 (PDB 1E6J) and protease (PDB 
4dqf). Coloured spheres indicate coevolving residues in each structure blue for p17, orange for p24 and red for 
protease. The areas highlighted in cyan indicate; the globular domain in p17, the Cyp A binding loop in p24 
and the enzyme active site in protease. Numbering is according to the HXB2 reference sequence. Coevolving 
residues represented in the p17 are limited to those present in the crystal structure.
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In general, immune responses in the protease were almost absent, weak and focused on a few peptides in 
Gag (Gag overlapping peptides 17, 23, 25, and 41), with no major changes in breadth or magnitude during the 
follow-up period (Table S1). Additionally, in order to characterize in detail the convergence between HIV-1 evo-
lutionary pathways derived from immunological pressure and treatment with PIs in Gag and protease, we merged 
immunological data with data obtained from the CAPS analysis for each patient. As shown in Fig. 5A–D, we did 
not find convergence between coevolving Gag sites obtained by CAPS and sites of CD8+ T-cell immune pressure. 
These data suggest an independent effect of PI-driven evolution of Gag and indicate no effect of immune pressure 
by CD8+ T cells on Gag-protease coevolution.
Discussion
The potency of PIs, which results from their multi-step inhibitory mechanism, leads to an unusual complexity of 
the mutational pathways to HIV-1 resistance12. A direct reflection of this phenomenon is that most of the patients 
who experience virological failure with PIs nowadays do so in the absence of drug resistance mutations at the 
active site of the viral protease8. The complex mutational dynamics of HIV-1 under treatment with PIs is not fully 
understood. Therefore, a better understanding of the HIV-1 evolutionary pathways is crucial when attempting to 
identify novel determinants of virological failure during treatment with PIs. This information could be useful to 
build molecular models and improve drug design to ensure long-term treatment efficacy.
Over the last few years, various studies have revealed the major contribution of Gag to changes in susceptibil-
ity to PIs in the presence or absence of mutations in HIV-1 protease7, 9–11, 26. However, most of these studies rely on 
unique patient-derived viral genetic backgrounds and cross-sectional analyses of bulk sequences that cannot cap-
ture the complex dynamics of Gag-protease evolution under pressure from PIs. To overcome previous study lim-
itations, we analysed longitudinal Gag-protease sequences over 9 years of PI-containing treatment in 4 patients. 
Moreover, we obtained Gag-protease sequences by SGA in order to avoid PCR artifacts and to accurately assess 
Gag-protease inter-mutational linkage by coevolution analysis. To our knowledge, no other experimental design 
has offered as much detail of Gag-protease mutational dynamics of HIV-1 evolution to identify Gag hotspots 
potentially involved in the development of resistance to PIs. Moreover, our data help to define Gag coevolution 
in the setting of pressure from PIs, thus excluding natural variation, common ancestors and the selective pressure 
from the immune system of this otherwise highly immunogenic region27, 28.
Our results demonstrate that more than 50% of correlated Gag-protease residues lie in the viral matrix outside 
cleavage sites and are present in more than 85% of the coevolving groups. The most frequent correlated Gag resi-
dues in the matrix clustered around helix 3 (E55 and R58), the α3/4 loop (P66, and Q69) and helix 5 (K98, D102, 
E104, S111, and A115) in the p17 crystal structure. These data are consistent with the identification of frequent 
Gag-protease correlations within the first 200 residues in Gag29. In addition, out of the Gag correlated residues in 
the matrix, residues 55 and 58 located at helix 3 forms the globular core of the matrix through antiparallel contacts 
Figure 4. Mapping of coevolving HIV-1 p17 and p24 sites at the quaternary protein structural level. (A) 
Solved crystal structure of p17 (PDB 1HIW) and (B) p24 (PDB 1E6J). Coloured spheres indicate coevolving 
Gag residues in blue for p17 and in orange for p24. Numbering is according to the HXB2 reference sequence. 
(C) Matrix trimers with blue areas highlighting coevolving residues; (D) Capsid hexamers with orange areas 
highlighting coevolving residues. Structures on the left represent proteins seen top-down, and structures on the 
right represent proteins seen top-up. Coevolving residues represented in the p17 are limited to those present in 
the crystal structure.
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with helix 4, which is key for the structural stability of the protein. Mutations in the globular core of the matrix 
have been previously shown to reduce HIV-1 susceptibility to lopinavir11. Thus supporting the contribution of 
correlated sites in the matrix to HIV-1 evolution under pressure of PIs and potential development of resistance.
At higher protein structural levels, correlated residues in the matrix defined protein sectors on the inner 
face of the trimer. These surfaces, which were distributed across the tips and the centre of the trimer, identified 
potential novel inter-protein interfaces. In line with our findings, previous studies associated these surfaces with 
interactions between the C-terminal domain of the gp41 Env protein and the matrix. Indeed, Env proteins are 
incorporated into HIV-1 particles in a matrix trimerization-dependent manner9, 30, 31. Therefore, modifications 
in matrix stability could affect virus fusogenicity. Of the coevolving p17 residues identified in our study, three out 
of them (residues 66, 69 and 98) have been shown to contribute to matrix stabilization and incorporation of Env 
into immature viral particles13, 30, 32. Thus, we hypothesized that the viral matrix may affect resistance of HIV-1 to 
PIs disturbing particle maturation and virus fusogenicity. Our observations support recent findings that describe 
the impact of Env in resistance of HIV-1 to PIs12.
Together with correlated residues in the matrix, our study identifies a group of correlated Gag-protease res-
idues in the capsid. These residues comprise only 6 positions of the longest Gag protein. Residues V215, M228, 
T248, N252, T280 and K331 were distributed across the NTD and CTD of the viral capsid. Positions V215, M228, 
T248, N252 and T280 clustered either in the CypA binding loop or nearby and organized in exposed surface areas 
of the capsid hexamer. The limited number of correlated residues in the capsid and their distribution restricted 
to exposed surface areas may be associated with the genetic fragility of the protein to mutational changes 16. 
Moreover, three of these positions (M228, T248, and N252) have previously been shown to compensate for fitness 
defects of p24 escape mutants driven by HIV-1–specific CD8+ T-cell responses33, 34. In addition, mutations in the 
CypA at position 219 have been shown to increase HIV-1 replication of PI-resistant variants25, 35. Thus, pointing 
towards evolutionary constraints in the capsid to modulate viral replicative capacity.
Our study provides novel insights into the contribution of Gag to protease evolution during the development 
of resistance of HIV-1 to PIs in two ways. We identify previously unknown residues and clusters of residues in 
Gag that are associated with the selection of PI resistance mutations in the protease (Supplementary Table 2). 
Moreover, our data demonstrate the role of the matrix as a hotspot of protease coevolution and pinpoint novel 
protein sectors in the matrix and the capsid that are associated with protease evolution under pressure from PIs. 
Figure 5. Correlated Gag resides and HIV-1 Gag-specific CD8+ T-cell responses. Neighbour-joining 
phylogenetic tree of Gag SGA nucleotide sequences represented for each study subject (A–D). Coloured dots 
represent SGA sequences from different time points, and numbers indicate sampling points. Bootstrap values 
above 60 are shown in the tree. The highlighted plots next to the tree represent Gag amino acid changes over 
time for each study subject by direct comparison with the earliest samples. Light blue shadows indicate Gag 
regions correlated with the protease, and blue lines on top of the highlighted plot show CD8+ T-cell responses 
to specific overlapping peptides in Gag.
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These findings may serve as a basis for future research into the potential mechanism of HIV-1 resistance to PIs 
of these regions.
Our study is subject to a series of limitations. First, we studied only four subjects with backbone treatments 
containing reverse transcriptase inhibitors (RTI) and switches of PIs over time. Therefore, we cannot completely 
exclude the influence by RTI backbone treatment on subsequent viral evolution. However, recent data suggests 
that there are minor genetic interactions between the RT and the Protease coding regions36 and  we can assume 
a minimal effect of RTI treatment in Gag-protease coevolutionary events. Second, we cannot exclude unknown 
interactions in immature Gag-pol polyproteins37, as structural mapping was performed in the mature protein 
crystal structures. Third, we did not perform direct measurements of viral susceptibility for PIs, and additional 
mutational, functional and structural studies of Gag correlated residues would be needed before conclusions can 
be drawn.
In summary, our study improves our understanding of Gag-protease dynamics of coevolution associated with 
HIV-1 constraints under pressure from PIs. In addition, our data underline the contribution of Gag structural 
proteins and identify novel residues and specific protein sectors that are potentially involved in the development 
of resistance of HIV-1 to PIs. Coevolution analysis of HIV-1 proteins when combined with those of additional 
functional and structural studies, may serve as a roadmap to guide the development of novel small molecules to 
increase treatment efficacy against HIV-1.
Methods
Study subjects. We studied 4 patients with chronic HIV-1 infection (PT1, PT2, PT3 and PT4) in whom 
resistance to PIs had evolved over a median of 4 years after initiation of treatment with PIs. The clinical param-
eters (median [IQR] for each of the patients) were as follows: PT1, 122 (39–158) CD4+ T cells/mm3; 69,000 
(21,000–450,000) HIV-RNA copies/ml; PT2, 389 (80–1,460) CD4+ T cells/mm3; 457 (169–5,500) HIV-RNA 
copies/ml; PT3, 635 (177–757) CD4+ T cells/mm3; 5,500 (80–154,000) HIV-RNA copies/ml; PT4, 471 (118–630) 
CD4+ T cells/mm3; 37,500 (80–160,160) HIV-RNA copies/ml. Longitudinal plasma and peripheral blood mono-
nuclear cell (PBMC) samples were available for all 4 patients (Fig. 1A).
Ethics Statement. All methods and experimental protocols were approved by the Ethics Committee of 
Hospital Germans Trias i Pujol. The patients provided their written informed consent to participate in the study. 
The study was conducted according to the principles expressed in the Declaration of Helsinki.
Bulk amplification of the HIV-1 Gag-protease coding region. Total viral RNA was extracted 
from longitudinal plasma samples with the QIAamp viral RNA mini kit (QIAGEN). Plasma samples 
with viral loads below 10,000 copies/ml, were concentrated at 23,000 g for 90 minutes at 4 °C by ultra-
centrifugation. Viral RNA was amplified by RT-PCR (Superscript One-Step, Thermo Fisher, Spain) 
with the following primer sets: MMOP3 5-AATCTCTAGCAGTGGCGCCCGAAC-3 (623-647HXB2) 
and MMOP5 5′-TAACCCTGCAGGATGTGGTATTCC-3′ (2849-2826HXB2). The amplification condi-
tions were as follows: 30 minutes at 50 °C, 2 minutes at 94 °C, 15 seconds at 94 °C, 30 seconds at 53 °C, 
and 3 minutes at 68 °C for 40 cycles. A second polymerization step was carried out to amplify the 
Gag-protease coding region using a nested PCR (Platinum Taq DNA polymerase, Thermo Fisher, Spain) 
with the specific primers BssHII 5′-TTGCTGAAGCGCGCACGGCAAG-3′ (703-724HXB2) and ClaIR 
5′-GGTACAGTATCGATAGGACTAATGGG-3′ (2575-2550HXB2). The PCR conditions were as follows: 30 sec-
onds at 94 °C, 30 seconds at 94 °C, 30 seconds at 50/52 °C and 2 minutes 68 °C for 40 cycles. PCR reactions were 
purified using Exo-sap to remove primers dimers and reagents at 37 °C for 5 minutes and inactivated at 80 °C for 
15 minutes.
Single genome amplification (SGA) of the HIV-1 Gag -protease coding region. Extracted total 
viral RNA was reverse-transcribed to single-strand cDNA using Superscript III Reverse Transcriptase (Thermo 
Fisher, Spain) with the primer MMOP5 5′-TAACCCTGCAGGATGTGGTATTCC-3′ (2849-2826HXB2), as previ-
ously described20. The cDNA was used immediately for PCR or stored frozen at −80 °C. The cDNA was serially 
diluted in water with herring sperm DNA solution at 1,000 ng/ml to increase reproducibility at the dilutions used 
for PCR amplification and underwent sets of PCR reactions with the primers as described in the previous section. 
The SGA cut-off value for positive wells was 30%, as described elsewhere20. Positive PCR reactions were purified 
by Exo-sap to remove primer-dimers and reagents at 37 °C for 5 minutes and inactivated at 80 °C for 15 minutes.
Sequence analyses. All sequences were obtained using Sanger reactions with the Macrogen service 
(Netherlands) and analyzed with Sequencher (Genecodes V). Sequences were aligned to HXB2 using the Bioedit 
package. Phylogenetic trees of bulk and SGA nucleotide sequences were constructed using the neighbour-joining 
phylogenetic method with 1,000 bootstrap replicates (MEGA version 5)38. Phylogenetic trees validated sequence 
specificity and absence of sample cross-contamination (Supplementary Figure 1). The Stanford University HIV 
Drug Resistance Database was used to identify protease drug resistance mutations. Drug resistance was inter-
preted based on mutation scoring (http://hivdb.stanford.edu/ web [accessed on August 2016]). Longitudinal SGA 
sequences were examined for amino acid variation over time using the highlighter program available at “https://
www.hiv.lanl.gov”.
Gag-protease coevolutionary analysis for protein sequences: CAPS. A total of 171 Gag-protease 
SGA sequences were aligned to the HXB2 reference sequence. SGA sequences were equally distributed across 
patients (PT1, n = 44; PT2, n = 38; PT3, n = 41; and PT4, n = 48) and follow-up points (before treatment with PIs 
and at the last time point available after introduction of PIs). We analysed total and patient-specific Gag-protease 
coevolution using a parametric model to identify coevolution events in protein-coding genes39. The model was 
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implemented using the program Coevolution Analysis for Protein Sequences (CAPS)40. Briefly, CAPS compares 
the correlated variance of the evolutionary rates of pairs of amino acid sites, in a protein alignment adjusted for 
the time since the divergence of the 2 sequences they belong to. This method compares the transition probability 
scores between pairs of sequences at 2 particular sites, using the blocks substitution matrix (BLOSUM)41. The 
BLOSUM matrix applied in CAPS for each protein alignment applied depend of average sequence identity as 
previously described39. The significance of the CAPS correlation values was assessed by randomization of pairs of 
sites in the alignment, calculation of their correlation values, and comparison of the real values with the distribu-
tion of 10,000 randomly sampled values. Statistical significance was set at < 0.01. In order to correct for multiple 
tests for non-independence of data, CAPS implemented the step-down permutation procedure in both methods 
and corrected the probabilities. Gag-protease coevolution groups were constructed as previously indicated39, 40. 
In brief, we analysed significantly correlated pairs (p < 0.01) to identify clusters of amino acids sharing signifi-
cant correlations among all the pairs and included those in a coevolving group (e.g. if 17 correlates with 23, 17 
correlates with 35, 17 correlates with 82 and 23 correlates with 82; then, 17, 23 and 82 form a coevolving group).
Entropy per site was calculated in SGA sequences using the entropy tool (Entropy-One) from the Los Alamos 
database.
Molecular modelling. Protein structures were obtained from RCSPDB—p24 (PDB 1E6J); p24 hexamer 
(PDB 3P05); p17 trimer (PDB 1HIW) and, protease (PDB 4dqf)—which are available at http://www.rcsb.org/
pdb/home/home.do. The structures represent the B clade virus and were modified to show Gag correlated sites 
with protease using the PyMOL Molecular Graphics System, Version 1.8 (Schrödinger).
HLA typing and assessment of HIV-1–specific CD8 + T-cell responses. High-resolution HLA 
class I typing for alleles A, B and Cw was performed using sequence-based typing methods. HIV-1–specific 
immune responses were assessed over time (Table S1) in cryopreserved PBMCs. In brief, after thawing, PBMCs 
were incubated with overlapping peptides covering the regions of HIV-1 Gag (48 peptides corresponding to the 
sequence HIV-1 SF2, 15-mers overlapping by 5 amino acids; CFAR/NIBSC, England) and protease (21 peptides 
corresponding to the consensus sequence of HIV-1 2001 for clade B, adapted 15-mers overlapping by 10 amino 
acids)42. Immune responses were measured using the interferon-γ (IFN-γ) ELISpot assay43. Wells were consid-
ered positive if they contained at least 50 spot-forming cells per 106 PBMCs or 3 times above the background 
level (2 × mean + 3 × STD). Assays were performed according to availability of cells. It was not possible to test all 
peptides for all patients and all time points.
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